PF-Atlas › Clinical Trials › NCT07441408

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

BMS-986278 · Phase 3

Registry ID
NCT07441408
Phase
Phase 3
Status
Not yet recruiting
Drug / intervention
BMS-986278
Sponsor
Bristol-Myers Squibb
Enrollment
2380
Locations
275

About this trial

The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).

View NCT07441408 on ClinicalTrials.gov →

Explore related

Admilparant / BMS-986278 — Treatment profileAll BMS-986278 trialsAll IPF trials

Related trials

BMS-986278 — NCT05932303BMS-986278 — NCT06003426BMS-986278 — NCT05985590BMS-986278 — NCT06025578BMS-986278 — NCT03981094
Medical disclaimer. This page summarizes public trial data for NCT07441408 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.